Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer.

doi:10.1158/1078-0432.CCR-21-1992

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Mar 2022

Cruz-Duarte Raquel, Rebelo de Almeida Cátia, Negrão Magda, Fernandes Afonso, Borralho Paula, Sobral Daniel, Gallego-Paez Lina M, Machado Daniel, Gramaça João, Vílchez José, Xavier Ana T, Ferreira Miguel Godinho, Miranda Ana R, Mansinho Helder, Brito Maria J, Pacheco Teresa R, Abreu Catarina, Lucia-Costa Ana, Mansinho André, Fior Rita, Costa Luís, Martins Marta

Abstract excerpt

PURPOSE: Cetuximab is an EGFR-targeted therapy approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC). However, about 60% of these patients show innate resistance to cetuximab. To increase cetuximab efficacy, it is crucial to successfully identify responder patients, as well as to develop new therapeutic approaches to overcome cetuximab resistance. EXPERIMENTAL DESIGN: We evaluated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Colonic Neoplasms

Share to Phospholipase C gamma

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Share to Proto-Oncogene Proteins p21(ras)

Share to Rectal Neoplasms

Share to Zebrafish

Source

Open in PubMed Open full text

Identifiers

PMID: 34980600
DOI: 10.1158/1078-0432.CCR-21-1992
PMCID: PMC9365369

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer.PMID 34980600Read ↗

Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer ModelsSemantic proximity Read ↗

FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.Semantic proximity Read ↗

Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.Semantic proximity Read ↗

Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.Semantic proximity Read ↗

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.Semantic proximity Read ↗

Model-based analysis of response and resistance factors of cetuximab treatment in gastric cancer cell linesSemantic proximity Read ↗

Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.Semantic proximity Read ↗

Cetuximab inhibits colorectal cancer development through inactivating the Wnt/β-catenin pathway and modulating PLCB3 expressionSemantic proximity Read ↗

Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers.Semantic proximity Read ↗

Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.Semantic proximity Read ↗

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan.Semantic proximity Read ↗

Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCCSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.